| UniProt ID | PSME3_HUMAN | |
|---|---|---|
| UniProt AC | P61289 | |
| Protein Name | Proteasome activator complex subunit 3 | |
| Gene Name | PSME3 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 254 | |
| Subcellular Localization | Nucleus . Cytoplasm. Localizes to the cytoplasm during mitosis following nuclear envelope breakdown at this distinct stage of the cell cycle which allows its interaction with MAP3K3 kinase.. | |
| Protein Description | Subunit of the 11S REG-gamma (also called PA28-gamma) proteasome regulator, a doughnut-shaped homoheptamer which associates with the proteasome. 11S REG-gamma activates the trypsin-like catalytic subunit of the proteasome but inhibits the chymotrypsin-like and postglutamyl-preferring (PGPH) subunits. Facilitates the MDM2-p53/TP53 interaction which promotes ubiquitination- and MDM2-dependent proteasomal degradation of p53/TP53, limiting its accumulation and resulting in inhibited apoptosis after DNA damage. May also be involved in cell cycle regulation. Mediates CCAR2 and CHEK2-dependent SIRT1 inhibition. [PubMed: 25361978] | |
| Protein Sequence | MASLLKVDQEVKLKVDSFRERITSEAEDLVANFFPKKLLELDSFLKEPILNIHDLTQIHSDMNLPVPDPILLTNSHDGLDGPTYKKRRLDECEEAFQGTKVFVMPNGMLKSNQQLVDIIEKVKPEIRLLIEKCNTVKMWVQLLIPRIEDGNNFGVSIQEETVAELRTVESEAASYLDQISRYYITRAKLVSKIAKYPHVEDYRRTVTEIDEKEYISLRLIISELRNQYVTLHDMILKNIEKIKRPRSSNAETLY | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Acetylation | ------MASLLKVDQ ------CCCCCCCCH | 14.64 | 22814378 | |
| 3 | Phosphorylation | -----MASLLKVDQE -----CCCCCCCCHH | 32.70 | 25003641 | |
| 6 | Acetylation | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | 23749302 | |
| 6 | Sumoylation | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | - | |
| 6 | Ubiquitination | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | - | |
| 6 (in isoform 2) | Ubiquitination | - | 49.40 | - | |
| 6 | 2-Hydroxyisobutyrylation | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | - | |
| 6 | Sumoylation | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | - | |
| 6 | Succinylation | --MASLLKVDQEVKL --CCCCCCCCHHHHH | 49.40 | 23954790 | |
| 12 | 2-Hydroxyisobutyrylation | LKVDQEVKLKVDSFR CCCCHHHHHHHHHHH | 41.67 | - | |
| 12 | Ubiquitination | LKVDQEVKLKVDSFR CCCCHHHHHHHHHHH | 41.67 | - | |
| 12 | Sumoylation | LKVDQEVKLKVDSFR CCCCHHHHHHHHHHH | 41.67 | - | |
| 12 | Acetylation | LKVDQEVKLKVDSFR CCCCHHHHHHHHHHH | 41.67 | 25953088 | |
| 12 | Sumoylation | LKVDQEVKLKVDSFR CCCCHHHHHHHHHHH | 41.67 | - | |
| 14 | Sumoylation | VDQEVKLKVDSFRER CCHHHHHHHHHHHHH | 37.97 | - | |
| 14 (in isoform 1) | Ubiquitination | - | 37.97 | 21890473 | |
| 14 | Ubiquitination | VDQEVKLKVDSFRER CCHHHHHHHHHHHHH | 37.97 | 21906983 | |
| 14 | Sumoylation | VDQEVKLKVDSFRER CCHHHHHHHHHHHHH | 37.97 | - | |
| 14 | Acetylation | VDQEVKLKVDSFRER CCHHHHHHHHHHHHH | 37.97 | 62154813 | |
| 14 (in isoform 2) | Ubiquitination | - | 37.97 | 21890473 | |
| 14 | 2-Hydroxyisobutyrylation | VDQEVKLKVDSFRER CCHHHHHHHHHHHHH | 37.97 | - | |
| 17 | Phosphorylation | EVKLKVDSFRERITS HHHHHHHHHHHHHHH | 29.23 | 23186163 | |
| 23 | Phosphorylation | DSFRERITSEAEDLV HHHHHHHHHHHHHHH | 27.08 | 26503892 | |
| 23 (in isoform 2) | Phosphorylation | - | 27.08 | 21406692 | |
| 24 (in isoform 2) | Phosphorylation | - | 32.22 | 24719451 | |
| 24 | Phosphorylation | SFRERITSEAEDLVA HHHHHHHHHHHHHHH | 32.22 | 29255136 | |
| 36 (in isoform 2) | Ubiquitination | - | 51.39 | 21890473 | |
| 36 | 2-Hydroxyisobutyrylation | LVANFFPKKLLELDS HHHHHCCHHHHCHHH | 51.39 | - | |
| 36 | Ubiquitination | LVANFFPKKLLELDS HHHHHCCHHHHCHHH | 51.39 | 21906983 | |
| 36 | Acetylation | LVANFFPKKLLELDS HHHHHCCHHHHCHHH | 51.39 | 23236377 | |
| 36 (in isoform 1) | Ubiquitination | - | 51.39 | 21890473 | |
| 37 | Acetylation | VANFFPKKLLELDSF HHHHCCHHHHCHHHH | 59.55 | 27452117 | |
| 37 (in isoform 2) | Ubiquitination | - | 59.55 | 21890473 | |
| 37 (in isoform 1) | Ubiquitination | - | 59.55 | 21890473 | |
| 37 | Ubiquitination | VANFFPKKLLELDSF HHHHCCHHHHCHHHH | 59.55 | 21890473 | |
| 43 | Phosphorylation | KKLLELDSFLKEPIL HHHHCHHHHHCCCCC | 45.14 | 21815630 | |
| 73 | Phosphorylation | VPDPILLTNSHDGLD CCCCEEECCCCCCCC | 31.09 | 27251275 | |
| 73 (in isoform 2) | Phosphorylation | - | 31.09 | 27251275 | |
| 75 | Phosphorylation | DPILLTNSHDGLDGP CCEEECCCCCCCCCC | 20.09 | 25159151 | |
| 84 | Phosphorylation | DGLDGPTYKKRRLDE CCCCCCCCCCCCHHH | 20.04 | - | |
| 85 | Ubiquitination | GLDGPTYKKRRLDEC CCCCCCCCCCCHHHH | 42.13 | - | |
| 86 | Ubiquitination | LDGPTYKKRRLDECE CCCCCCCCCCHHHHH | 32.13 | - | |
| 92 | Glutathionylation | KKRRLDECEEAFQGT CCCCHHHHHHHHCCC | 5.98 | 22555962 | |
| 99 | Phosphorylation | CEEAFQGTKVFVMPN HHHHHCCCEEEECCC | 17.16 | 28555341 | |
| 100 | Ubiquitination | EEAFQGTKVFVMPNG HHHHCCCEEEECCCC | 40.26 | - | |
| 110 (in isoform 1) | Ubiquitination | - | 38.17 | 21890473 | |
| 110 | Methylation | VMPNGMLKSNQQLVD ECCCCCCCCCHHHHH | 38.17 | 44500383 | |
| 110 | Ubiquitination | VMPNGMLKSNQQLVD ECCCCCCCCCHHHHH | 38.17 | 21890473 | |
| 110 (in isoform 2) | Ubiquitination | - | 38.17 | 21890473 | |
| 111 | Phosphorylation | MPNGMLKSNQQLVDI CCCCCCCCCHHHHHH | 35.59 | 21712546 | |
| 121 (in isoform 2) | Ubiquitination | - | 45.19 | 21890473 | |
| 121 | Methylation | QLVDIIEKVKPEIRL HHHHHHHHHCHHHHH | 45.19 | - | |
| 121 | 2-Hydroxyisobutyrylation | QLVDIIEKVKPEIRL HHHHHHHHHCHHHHH | 45.19 | - | |
| 121 | Ubiquitination | QLVDIIEKVKPEIRL HHHHHHHHHCHHHHH | 45.19 | 22053931 | |
| 121 (in isoform 1) | Ubiquitination | - | 45.19 | 21890473 | |
| 132 | Acetylation | EIRLLIEKCNTVKMW HHHHHHHHCCHHHHH | 26.28 | 25953088 | |
| 132 | Ubiquitination | EIRLLIEKCNTVKMW HHHHHHHHCCHHHHH | 26.28 | - | |
| 167 | Phosphorylation | ETVAELRTVESEAAS HHHHHHHCHHHHHHH | 41.05 | 28152594 | |
| 170 | Phosphorylation | AELRTVESEAASYLD HHHHCHHHHHHHHHH | 28.35 | 28152594 | |
| 174 | Phosphorylation | TVESEAASYLDQISR CHHHHHHHHHHHHHH | 33.02 | 28152594 | |
| 175 | Phosphorylation | VESEAASYLDQISRY HHHHHHHHHHHHHHH | 15.01 | 20860994 | |
| 180 | Phosphorylation | ASYLDQISRYYITRA HHHHHHHHHHHHHHH | 14.48 | 28152594 | |
| 195 | 2-Hydroxyisobutyrylation | KLVSKIAKYPHVEDY HHHHHHHCCCCHHHH | 63.89 | - | |
| 195 (in isoform 1) | Ubiquitination | - | 63.89 | 21890473 | |
| 195 | Acetylation | KLVSKIAKYPHVEDY HHHHHHHCCCCHHHH | 63.89 | 19608861 | |
| 195 | Ubiquitination | KLVSKIAKYPHVEDY HHHHHHHCCCCHHHH | 63.89 | 19608861 | |
| 196 | Phosphorylation | LVSKIAKYPHVEDYR HHHHHHCCCCHHHHC | 6.91 | 28152594 | |
| 205 | Phosphorylation | HVEDYRRTVTEIDEK CHHHHCCCEEECCHH | 23.84 | 21082442 | |
| 207 | Phosphorylation | EDYRRTVTEIDEKEY HHHCCCEEECCHHHH | 26.98 | 21082442 | |
| 208 | Acetylation | DYRRTVTEIDEKEYI HHCCCEEECCHHHHH | 44.07 | 19608861 | |
| 208 | Ubiquitination | DYRRTVTEIDEKEYI HHCCCEEECCHHHHH | 44.07 | 19608861 | |
| 208 (in isoform 2) | Acetylation | - | 44.07 | - | |
| 208 (in isoform 2) | Ubiquitination | - | 44.07 | 21890473 | |
| 212 | 2-Hydroxyisobutyrylation | TVTEIDEKEYISLRL CEEECCHHHHHHHHH | 52.66 | - | |
| 212 | Acetylation | TVTEIDEKEYISLRL CEEECCHHHHHHHHH | 52.66 | 23236377 | |
| 212 | Methylation | TVTEIDEKEYISLRL CEEECCHHHHHHHHH | 52.66 | - | |
| 214 | Phosphorylation | TEIDEKEYISLRLII EECCHHHHHHHHHHH | 13.59 | - | |
| 222 | Phosphorylation | ISLRLIISELRNQYV HHHHHHHHHHHHCCC | 24.47 | 24719451 | |
| 237 | Acetylation | TLHDMILKNIEKIKR CHHHHHHHHHHHHCC | 44.98 | 27452117 | |
| 247 | Phosphorylation | EKIKRPRSSNAETLY HHHCCCCCCCCCCCC | 30.54 | 25159151 | |
| 248 | Phosphorylation | KIKRPRSSNAETLY- HHCCCCCCCCCCCC- | 41.14 | 25159151 | |
| 252 | Phosphorylation | PRSSNAETLY----- CCCCCCCCCC----- | 29.01 | 23403867 | |
| 254 | Phosphorylation | SSNAETLY------- CCCCCCCC------- | 24.75 | 23403867 | |
| 260 (in isoform 2) | Phosphorylation | - | 24719451 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 247 | S | Phosphorylation | Kinase | CHK2 | O96017 | PSP |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PSME3_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-195, AND MASS SPECTROMETRY. | |